We tested two BCR signaling inhibitors (SYK inhibitor R406 and IKKβ inhibitor BMS345541) in three B cell lymphoma cell lines derived from GCB-DLBCL (SUDHL4, CD10 +/BCL6 +), ABC-DLBCL (SUDHL8, CD10−/BCL6−) and primary effusion lymphoma (BCBL1, CD10−/BCL6−). This evidence concerns the gene BCR and primary effusion lymphoma.